Serum levels of human epididymis protein 4 are more stable than cancer antigen 125 in early and mid‐term pregnancy. Issue 11 (20th August 2018)

• Record Type: Journal Article
• Authors: Wang, Zhiheng; Zhou, Fangfang; Xiao, Xirong; Ying, Chunmei
• Is Part Of: Journal of obstetrics and gynaecology research. Volume 44:Issue 11(2018)
• Page Start: 2053
• Page End: 2058
• Publication Date: 2018-08-20
• Subjects: cancer antigen 125 -- human epididymis protein 4 -- pregnancy -- threatened abortion; Gynecology -- Periodicals; Obstetrics -- Periodicals; 618.1005
• DOI: 10.1111/jog.13764
• Languages: English
• ISSNs: 1341-8076

Abstract

Abstract: Aim: Previous studies have shown serum human epididymis protein 4 (HE4) and cancer antigen 125 (CA125) levels could serve as predictive markers in the diagnosis of ovarian cancer. However, HE4 levels have been less well studied during pregnancy, especially in threatened abortion, while CA125 levels were fluctuated. Our study aimed to assess the stability of HE4 and CA125 levels through trimesters and in cases of threatened abortion. Methods: Forty‐six nonpregnant women (control), 167 healthy pregnant women and 46 pregnant threatened abortion (TA; 8–12 weeks pregnancy) women who visited the Obstetrics and Gynecology Hospital of Fudan University from September to December 2017 were recruited. The healthy pregnant women group included 57 women in the first trimester (T1), 55 in the second (T2) and 55 in the third (T3). Serum levels of HE4 and CA125 were measured by electrochemiluminescent immunoassay. Results: Both HE4 and CA125 levels in the T3 group were significantly higher than in the control group ( P < 0.001). There was no difference in HE4 between the control, T1 and T2 groups, while levels of CA125 in T1 group were elevated ( P < 0.001). There was no difference in HE4 levels between the TA, control and T1 groups. However, the levels of CA125 in the TA group were much higher ( P < 0.05). Conclusion: The level of HE4 was found to be more stable than that of CA125 in early and mid‐pregnancy and in cases of threatened abortion.